37 results about "Arthritis- rheumatoid arthritis" patented technology

The invention discloses an epitope of rheumatoid arthritis and application thereof, belonging to the technical field of immunologic diagnosis. The epitope is a polypeptide, and the amino acid sequence is disclosed as SEQ ID NO:1 in the sequence table. ELISA detection and patient serum reaction condition indicate that the epitope polypeptide can be specifically combined with IgG in the patient serum, and does not react with the serum of a health person. The epitope polypeptide can be used for preparing medicines for diagnosing rheumatoid arthritis.

The invention discloses a rheumatoid-arthritis-related single-gene single nucleotide polymorphism site and an application thereof. According to the technical scheme disclosed by the invention, the application is an application of substances for detecting polymorphism or genotype of rs1050501 in human genome in preparation of products for screening patients with rheumatoid arthritis, and an application of substances for detecting polymorphism or genotype of rs1050501 in human genome in preparation of products for predicting the illness states of the patients with rheumatoid arthritis. The substances for detecting the polymorphism or genotype of rs1050501 can be combined with other substances (such as other substances for detecting leprosy-related single nucleotide polymorphism or genotype) to prepare the products for screening patients with leprosy or predicting the illness states of the patients with rheumatoid arthritis.

The invention discloses an exosome miRNA marker of rheumatoid arthritis and a kit and belongs to the technical field of biological detection. According to the exosome miRNA marker of rheumatoid arthritis, an exosome miR-204-5p sequence and a corresponding primer can be used for preparing a rheumatoid arthritis diagnostic kit; very high sensitivity and specificity are realized; and the exosome miRNA marker of the rheumatoid arthritis is beneficial for promoting the developments of early diagnosis, treatment predication and recurrence monitoring of the rheumatoid arthritis in China.

The invention discloses application of metallothionein-1 in the preparation of drugs for inhibiting rheumatoid arthritis. The metallothionein-1 inhibits the differentiation of Th17 cells, promotes the differentiation of regulatory T cells, regulates the balance of Th17 / Treg under the state of CIA, and participates in the generation and development of rheumatoid arthritis; and the metallothionein-1 inhibits the expression of various inflammatory factors related to rheumatoid arthritis by a negative feedback regulation mechanism, and promotes the expression of immune suppression factors (IL-10 and TGF-beta) by a positive feedback regulation mechanism, and therefore, inflammatory response and pathologic change of rheumatoid arthritis are reduced, the process of the rheumatoid arthritis is delayed, and clinical evidence and a drug target are provided for the diagnosis and treatment of autoimmune diseases related to rheumatoid arthritis.

The invention belongs to the medicine field and particularly discloses application of benzoyl aconine in preparation of rheumatoid arthritis therapeutic drugs, the benzoyl aconine is taken as a natural medical material extractive, remarkable multi-acting target, low toxicity and high-efficiency therapeutic effects to the rheumatoid arthritis can be realized through multiple action mechanisms of anti-inflammation and detumescence, ankle pathologic change reduction, immune visceral organ pathologic change reduction and / or serum cell factor reduction, the cure rate of the rheumatoid arthritis patients is increased, the possibility of the medicine kinds and the dosage is reduced, and the benzoyl aconine has a remarkable and advanced meaning in the preparation of the rheumatoid arthritis therapeutic drugs.

Rheumatoid arthritis is efficiently diagnosed with improved patient's convenience using a rheumatoid arthritis diagnosis composition and a kit, each including cyclic citrullinated peptide (CCP), a rheumatoid arthritis diagnosis method using the CCP, the rheumatoid arthritis diagnosis composition, or the kit, a method of obtaining information for rheumatoid arthritis diagnosis, and a method of screening a novel diagnostic marker for rheumatoid arthritis.

A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.

The invention relates to the field of medical diagnosis, in particular to susceptibility loci of rheumatoid arthritis and application of the susceptibility loci. The discovered susceptibility loci ofrheumatoid arthritis are selected from one or more of A obtained through mutation of C located at the 32609965 position on the chromosome 6, and / or T obtained through mutation of C located at the 32551894 position on the chromosome 6. By utilizing the discovered SNP loci, rheumatoid arthritis can be quickly predicted, when symptoms of rheumatoid arthritis are not expressed, or a baby is just born,the disease risk can be predicted, and the accurate and efficient purpose is achieved.

Rheumatism pain alleviating medicinal liquor is prepared from, by weight, 50 g of Periploca forrestii Schltr, 20 g of olibanum, 20 g of myrrh, 10 g of centipedes, 5 g of borneol, 20 g of zaocys dhumnade, 20 g of thunder god vine, 20 g of ephedra, 20 g of safflowers and 50 g of baijiu. The rheumatism pain alleviating medicinal liquor has the effects of dispelling wind and eliminating dampness, promoting blood circulating to remove blood stasis and relieving swelling and pain, is used for preventing and treating various kinds of arthritis such as rheumatoid arthritis and achieves the obvious effect.

The invention discloses a drug combination for treating rheumatism arthritis and a preparation method thereof. The drug combination for treating rheumatism arthritis comprises, by weight, 10-30 parts of panax japonicas, 10-30 parts of astilbe chinensis, 10-30 parts of paris polyphylla, 20-60 parts of clematis henryi oliv, 15-45 parts of toddalia asiatualam and 15-45 parts of Indian damnacanthus herbs. The preparation method includes the steps that raw medicines are weighed separately and subjected to 160-mesh sieving, and the raw medicines are obtained; and the raw medicines including the panax japonicas, the astilbe chinensis, the paris polyphylla, the clematis henryi oliv, the astilbe chinensis and the Indian damnacanthus herbs are mixed evenly, and the drug combination for treating rheumatism arthritis is obtained. The drug combination for treating rheumatism arthritis has the effects of dispelling wind, eliminating dampness, dispersing blood stasis, relieving pain, promoting qi to activate blood, warming and activating meridian, and achieving nourishing and strengthening, has significant clinical effects and has no obvious toxic or side effects. The drug combination for treating rheumatism arthritis has a significant therapeutic effect on arthritis induced by a complete Freund's adjuvant, has good anti-inflammatory and analgesic effects, achieves the pharmacological function significantly superior to that of a single medicinal material and other compatible combinations, plays a synergetic interaction and has low toxic and side effects.

The invention relates to a medicine for treating rheumatoid arthritis, wherein the effective component is astragalin, and the effective concentration is 10-1000 [mu]M. The astragalin is mixed with pharmaceutically acceptable pharmaceutical adjuvants to form powders, ointments, powders, injections, aqueous solutions, enteric-coated sustained-release preparations or injections. As proved by animal experiments, the astragalin can reduce clinical symptom score and synovial fluid volume of mice with collagen-induced rheumatoid arthritis, inhibit expression of matrix metalloproteinase of human synoviocytes induced by TNF alpha, and effectively improve rheumatoid arthritis symptom. The invention also relates to the use of astragalin in the preparation of medicine or health product for preventingand treating rheumatoid arthritis. The effective concentration of astragalin is 10-1000 [mu]M.

The invention relates to a novel application of eleutheroside E, in particular to an application of the eleutheroside E in preparation of a rheumatoid arthritis treatment medicine and medicine composition for treating the rheumatoid arthritis. The medicine composition for treating the rheumatoid arthritis can be prepared into tablets, capsules, a dissolved medicine, drops, granules, an ointment or an injection through the eleutheroside E with purity higher than 98% (mass percentage) added with universal auxiliary medical components. Pharmacology experiment results show that the eleutheroside E can remarkably improve the joint swelling condition of the rheumatoid arthritis, reduce the arthritis index, reverse pathologic change of arthritis, has no critical defects of clinically common medicines, and has the function of the rheumatoid arthritis resistance with high efficiency and low toxicity. Therefore, the eleutheroside E can be used for preparing the medicine for treating the rheumatoid arthritis. The invention provides a novel medicine source for treating the rheumatoid arthritis.

The invention relates to Gypensapogenin B for treating immune inflammation and preparing a medicament for treating rheumatoid arthritis. By using terfenadine and diclofenac sodium as contrasts, the Gypensapogenin B has definite treatment effect. The application of the Gypensapogenin B in preparation of the medicament for treating rheumatoid arthritis is disclosed for the first time, the skeleton type is a brand-new skeleton type, the Gypensapogenin B has unexpected strong inhibiting activity on the rheumatoid arthritis, the probability of giving any revelation by other compounds does not exit, and the Gypensapogenin B has predominant substantial characteristics and obviously has a remarkable progress in prevention and treatment of the rheumatoid arthritis.

The invention discloses an application of hsa-MiR-17-5p as a diagnostic marker of rheumatoid arthritis. The application of hsa-MiR-17-5p as a diagnostic marker of rheumatoid arthritis firstly demonstrates that hsa-MiR-17-5p is overexpressed in synovial tissue of rheumatoid arthritis patients and secreted into serum, and hsa-MiR-17-5p level is increased significantly. Therefore, the present invention provides a novel diagnostic marker of rheumatoid arthritis, namely serum hsa-MiR-17-5p, which has good specificity and high sensitivity for rheumatoid arthritis, and overcomes the shortcomings of poor specificity and lower sensitivity of rheumatoid factor RF and anti-cyclic citrulline antibody ACPA, which are the existing diagnostic markers of rheumatoid arthritis, and has good diagnostic valuefor rheumatoid arthritis.

A polypeptide that binds to immune antibodies, with three arginine side chains modified to be electrically neutral or electronegative amino acids in its sequence. Two non-adjacent cysteine ​​side chain sulfhydryl groups on these polypeptide sequences form a disulfide bond to form a ring. This kind of polypeptide can not only combine with rheumatoid arthritis autoimmune antibody, but also have high affinity to HLA-DR. It is verified by experiments that the specificity of combining the polypeptide with the autoimmune antibody of rheumatoid arthritis is greater than 95%, and the detection sensitivity of the autoimmune antibody of rheumatoid arthritis is greater than 75%. Compared with similar products sold in the market, its sensitivity is significantly improved, which is more conducive to the in vitro detection of rheumatoid arthritis autoimmune antibodies.

The invention discloses an application of steroids of extract of Fissistigma oldhamii(Hemsl.) Merr. in preparing drugs for treating rheumatoid arthritis. The structural formula of the steroids is as shown in the specification; wherein the stub symbol in the structural formula can be double bonds or single bond; R1, R2 and R3 are respectively -OH or -CH3 or -CH2H5. The activity of the steroids in suppressing synoviocyte proliferation of rheumatoid arthritis is discovered for the first time, and the steroids can be applied to preparation of the drugs for treating rheumatoid arthritis.

The invention discloses Aphanamixoid A for treating immunity inflammation, and particularly relates to Aphanamixoid A for preparing a medicine for treating rheumatoid arthritis. The rheumatoid arthritis is definite in curative effect by taking terfenadine and diclofenac sodium as references. The application of the Aphanamixoid A in preparation of the medicine for treating the rheumatoid arthritis is firstly disclosed because a skeleton type belongs to a fire-new skeleton type and the inhibitory activity of the Aphanamixoid A on the rheumatoid arthritis is inconceivably high; and the Aphanamixoid A has outstanding substantiality characteristic without possibility of any inspiration given by other compounds and obviously achieves the outstanding progress by being used for preventing and treating the rheumatoid arthritis.

The invention belongs to the technical field of medicines, and particularly relates to a medical composition for treating rheumatoid arthritis and a preparation method and application of the medical composition. The medicine can obviously restrain hyperplasia of synovium of joints and moistening of inflammatory cells of patients suffering from rheumatoid arthritis, can improve vascular proliferation or pannus formation, and cartilage invasion and destroy, can improve the joint damage of the patients, can alleviate arthrocele, and can restrain generation of inflammatory cell factors in serum, so that the medical composition has good treatment effect on the patients suffering from the rheumatoid arthritis.

Provided are an inhibitor, a prophylactic, and a therapeutic agent for rheumatoid arthritis that have no side effects and that can correct immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent for rheumatoid arthritis contain a Euglena-derived material as an active ingredient. The inhibitor, the prophylactic and the agent are used as an antirheumatic drug for controlling the activity of rheumatoid arthritis by alleviating immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are also used for a living individual who has not been definitively diagnosed with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are continuously administered to the living individual from any point before definitive diagnosis of rheumatoid arthritis to any point after the definitive diagnosis. The Euglena-derived material is at least one material selected from the group including Euglena algae, paramylon derived from the Euglena, water-soluble amorphous paramylon prepared by treating the paramylon with alkali and neutralizing the treated paramylon, and emulsion paramylon prepared by ejecting a solution of the paramylon from a narrow bore nozzle at a very high pressure to cause the solution to collide with a collision surface.

The invention specifically discloses application of a combination of benzoylaconitine and paeoniflorin to preparation of a drug used for treating rheumatoid arthritis, and the prepared drug, belongingto the field of medicines. According to the invention, the combination of benzoylaconitine and paeoniflorin benzoyl aconitine exerts the synergistic multiple-effect functions of eliminating inflammations, easing pain, alleviating the synovial hyperplasia of joints, inhibiting the formation of pannus, reducing the infiltration of inflammatory cells and reducing bone destruction and / or pathologicalchanges of ankle joints by inhibiting the generation of serum PGE2, regulating serum cytokines (IL-1beta, TNF-alpha and VEGF), inhibiting the synthesis and secretion of IgG, and / or regulating the expression of STAT1 and STAT3 in a JAK-STAT signaling pathway; and the combination has multi-effect-target low-toxicity high-efficiency significant therapeutic effect on rheumatoid arthritis, increases the cure rate of patients with rheumatoid arthritis, and reduces the varieties and dosages of used drug; and application of the combination to the preparation of the drug used for treating rheumatoid arthritis has outstanding significant progressive significance.

The invention discloses Chukrasone A used for treating immunity inflammation. When seldane and diclofenac sodium are used as control samples, curative effect of Chukrasone A is clear in preparation of medicines used for treating rheumatoid arthritis. The applications of Chukrasone A in preparation of medicines used for treating rheumatoid arthritis is discloses for the first time. The molecular skeleton is novel, so that the inhibitory activity on rheumatoid arthritis is surprisingly strong, and it is impossible to estimate the inhibitory activity according to the inhibitory activities of other compounds. Chukrasone A possesses outstanding substantiality, and the applications of Chukrasone A in prevention and cure of rheumatoid arthritis possess significant advantages.

The invention provides novel polypeptide used for diagnosis of rheumatoid arthritis. An IgG (immunoglobulin G) type antibody of antigen of the polypeptide has high sensitivity and specificity in diagnosis of rheumatoid arthritis.

The invention provides Phyllanthoid A for treating immune inflammation, which is a medicament for treating rheumatoid arthritis. By adopting terfenatine and diclofenac sodium as controls, Phyllanthoid A has an exact curative effect, and is disclosed for the first time. The frame model is a brand-new frame model, and Phyllanthoid A has a strong activity in treating rheumatoid arthritis, has a highlighted substantial characteristic, and is remarkably progressed when being used for preventing and treating rheumatoid arthritis.